![]() | ![]() |
Formats:
|
||||||||||||||
Copyright © 2007, Cold Spring Harbor Laboratory Press A Slicer-independent role for Argonaute 2 in hematopoiesis and the microRNA pathway 1 The Laboratory for Lymphocyte Signaling, The Rockefeller University, New York, New York 10021, USA; 2 Wellcome Trust/Cancer Research, UK Gurdon Institute and Department of Biochemistry, University of Cambridge, Cambridge CB2 1QN, United Kingdom; 3 Wellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, United Kingdom 4Present address: European Molecular Biology Laboraory, Mouse Biology Unit, via Raminari 32, 00015 Monterotondo Scalo (RM), Italy. 5Corresponding authors.E-MAIL donal.ocarroll/at/embl-monterotondo.it; FAX 39-060900-91406.. 6E-MAIL tarakho/at/mail.rockefeller.edu; FAX (212) 327-8258. Received April 30, 2007; Accepted June 5, 2007. This article has been cited by other articles in PMC.Abstract Binding of microRNA (miRNA) to mRNA within the RNA-induced silencing complex (RISC) leads to either translational inhibition or to destruction of the target mRNA. Both of these functions are executed by Argonaute 2 (Ago2). Using hematopoiesis in mice as a model system to study the physiological function of Ago2 in vivo, we found that Ago2 controls early development of lymphoid and erythroid cells. We show that the unique and defining feature of Ago2, the Slicer endonuclease activity, is dispensable for hematopoiesis. Instead, we identified Ago2 as a key regulator of miRNA homeostasis. Deficiency in Ago2 impairs miRNA biogenesis from precursor-miRNAs followed by a reduction in miRNA expression levels. Collectively, our data identify Ago2 as a highly specialized member of the Argonaute family with an essential nonredundant Slicer-independent function within the mammalian miRNA pathway. Keywords: Ago2, Slicer, microRNA, hematopoeisis MicroRNAs (miRNAs) are genome-encoded 21- to 23-base-pair (bp) RNA molecules that post-transcriptionally regulate gene expression through the inhibition of translation and/or stability of target mRNAs. MiRNA-mediated gene silencing is executed by the multiprotein RNA-induced silencing complex (RISC). At the core of RISC are Dicer and an Argonaute (Ago) protein that interact to generate miRNA and execute their function. Dicer cleaves miRNA from its precursors (Grishok et al. 2001; Hutvagner et al. 2001; Ketting et al. 2001; Knight and Bass 2001), whereas Ago proteins (Ago1–4) bind miRNA (Lingel et al. 2003; Song et al. 2003; Yan et al. 2003) and mediate gene silencing (Hammond et al. 2001; Hutvagner and Zamore 2002). The mechanism of RISC-mediated gene silencing depends on the degree of complementarity between the miRNA and its target. Binding of miRNA–RISC to a partially complementary mRNA results in silencing through the inhibition of translation or mRNA degradation by catabolism within processing bodies (for review, see Pillai et al. 2007). In turn, direct cleavage or “slicing” of mRNA that is solely catalyzed by Ago2 (Liu et al. 2004; Meister et al. 2004; Song et al. 2004) requires perfect or near-perfect complementarity between the miRNA and the target (Hutvagner and Zamore 2002; Doench et al. 2003). To date, a single mammalian miRNA has been shown to direct Ago2-mediated slicing (Mansfield et al. 2004; Yekta et al. 2004); however, the ability of Ago2 to slice significantly mismatched targets in vitro indicates that the complementarity rules may not be as stringent as suggested (Martinez and Tuschl 2004). While the function of Ago2’s Slicer activity as the catalytic engine that powers RNA interference (RNAi) is understood, the general in vivo physiological importance of Ago2 and its endonuclease activity within the miRNA pathway remains largely unknown. Results and Discussion The potent regulatory function of miRNA in hematopoiesis (Chen et al. 2004; Cobb et al. 2005; Fazi et al. 2005; Muljo et al. 2005) makes this process attractive for the investigation of the physiological significance of Ago2. We therefore studied the development of the lymphoid and erythroid lineages derived from Ago2−/− bone marrow cells. The latter cells were produced by inducible inactivation of the Ago2 gene in bone marrow progenitors followed by the generation of Ago2−/− hematopoietic system in lethally irradiated wild-type mice (Supplementary Fig. S1). This approach enables the analysis of the bone marrow cell-intrinsic Ago2 function. Mice reconstituted with Ago2−/− or control Ago2fl/fl bone marrow cells are hereafter referred to as Ago2−/− or Ago2fl/fl mice, respectively. Analysis of mice 6–8 wk after reconstitution revealed that Ago2−/− bone marrow cells give rise to hematopoietic cells of various lineages (data not shown). However, the differentiation of the B lymphoid as well as erythroid lineages diverges significantly from the wild-type developmental pattern. Deficiency in Ago2 does not interfere with the generation of early pro-B (B220loCD43+IgM−) cells in the bone marrow, but affects further pre-B (B220loCD43−IgM−) cell differentiation and the subsequent generation of peripheral B cells (Fig. 1A
To directly test the physiological significance of “slicing,” we evaluated the ability of bone marrow cells deficient for Ago2’s “Slicer” endonuclease activity to support erythropoiesis in the bone marrow. For these purposes, we employed the Ago2D669A point mutant that is endonuclease inactive in vitro (Liu et al. 2004) and in vivo (Supplementary Fig. S2). Ago2−/− bone marrow cells were complemented with exogenous wild-type or Slicer-inactive Ago2 and used to generate bone marrow chimeras. Exogenous wild-type Ago2 and Slicer-inactive Ago2 were expressed at similar levels in both the bone marrow and bone marrow-derived splenic cells of reconstituted mice (Supplementary Fig. S3A). Most importantly, expression of either wild-type Ago2 or Slicer-inactive Ago2 could cure the impaired erythropoiesis and anemia caused by Ago2 deficiency. The expression of Slicer-inactive Ago2 restored the wild-type pattern of erythroid development in the bone marrow and spleen, rescuing ineffective erythropoiesis, erythroid hyperplasia, and splenomegaly (Fig. 2A
The irrelevance of Ago2-mediated slicing in hematopoiesis suggested an additional and essential role for Ago2 in the miRNA pathway. Earlier studies pointed to the potential involvement of Ago2 in miRNA homeostasis. Ago2 directly binds miRNA and is a component of the ribonucleoprotein complex that mediates miRNA biogenesis (Chendrimada et al. 2005; Gregory et al. 2005; Haase et al. 2005; Maniataki and Mourelatos 2005; Meister et al. 2005; Lee et al. 2006). To address the role of Ago2 in regulation of miRNA homeostasis, we measured the expression levels of miRNAs in Ago2−/− erythroblasts. Using miRNA microarray analysis, we observed a reduction in the levels of miRNAs in Ago2−/− erythroblasts compared with Ago2fl/fl controls (Fig. 3A
The arrested biogenesis of miRNA caused by the absence of Dicer is associated with accumulation of some but not all pre-miRNAs (Yi et al. 2006). Therefore, the accumulation of pre-miR-24 and pre-miR-199a in Ago2−/− fibroblasts, two pre-miRNAs that are readily detectible in wild-type fibroblasts, indicates a crucial role for Ago2 in miRNA biogenesis (Fig. 4A
Our data identify Ago2 as a key regulator of B lymphoid and erythroid development and function. We suggest that the hemaopoieitic defects arise from a reduced threshold of miRNA-mediated gene silencing due to the overall reduction of miRNAs and the loss of Ago2-mediated translational control. The fact that the Slicer activity of Ago2 is not required for erythropoiesis as well as the development of lymphoid cells provides genetic evidence that mRNA cleavage does not play a general role in the regulation of miRNA-mediated gene silencing in vivo. Our data demonstrate that Ago2 is highly specialized member of the Argonaute family with a crucial function within RISC in the regulation of miRNA homeostasis. This may be analogous to Argonautes in Caenorhabditis. elegans, where recent studies have revealed that distinct Argonautes have specialized functions and act sequentially in the RNAi pathway (Yigit et al. 2006). Materials and methods Generation of an Ago2 conditional allele in mice The Ago2 locus contains 16 exons. The targeting strategy allows Cre-mediated deletion of exons 9–11. This deletion excludes in-frame splicing of exon 8 to exons 12–16, and leads to the functional inactivation of Ago2 due to partial deletion of the PAZ domain and loss of RNase activity. In addition, according to the rules of RNA surveillance (Hentze and Kulozik 1999), the in-frame stop codons generated by frame-shift mutations introduced by the deletion of exons 9–11 is likely to destabilize the resulting primary transcript RNA and prevent production of a truncated Ago2 protein. The Ago2 gene targeting vector (pDTA–TK–Ago2) carries a neomycin resistance (neor) gene flanked with two frt sites, a loxP site (neor–frt2–loxP cassette) located 3′ of exon 11 and a loxP site (5′loxP) within the intron between exons 8 and 9. The Ago2 targeting construct was transfected into E14.1 embryonic stem (ES) cells. Southern blotting of the individual ES cell clone-derived genomic BamHI-digested DNA with probe 12i was used to identify homologous recombinants. A 4.2-kb DNA fragment corresponds to the wild-type Ago2 locus, and integration of the neor–frt2–loxP cassette 3′ of exon 11 introduces an additional BamHI site, thus increasing the size of the BamHI DNA fragment recognized by probe 12i to 5.0 kb. Targeted ES cells were used to generate mice heterozygous for the Ago2-targeted allele. These mice were then crossed to the FLP-expressing transgenic mice (FLPeR) (Farley et al. 2000) to remove the frt-flanked neor cassette, resulting in the generation of Ago2 loxP allele (Ago2 fl allele). Generation of Ago2−/− bone marrow and analysis of bone marrow chimeras To inactivate the Ago2 gene in the bone marrow, Ago2fl/fl mice (6–12 wk of age) that carry the MxCre transgene (Kuhn et al. 1995) (Ago2fl/fl;MxCre mice) received three i.p. injections of 250 μg per mouse of pI:pC, spaced 3 d apart. Mice were sacrificed no earlier than 10 d after the last injection and bone marrow cells were isolated and transferred into lethally irradiated (875 R) C57/Bl6 mice (6 × 106 to 7 × 106 cells per recipient). Bone marrow cells derived from Ago2fl/fl mice treated with pI:pC as described above were used as control. Bone marrow-reconstituted mice were maintained on medicated water (1000 U/mL polymixin B, 1.1 g/L neomycin sulfate) for 4 wk after reconstitution and were analyzed 6–8 wk or 3 mo after transfer. Isolation of spleen and bone marrow and subsequent FACS analysis were performed as described (Socolovsky et al. 2001; Mecklenbrauker et al. 2002). Blood parameters were analyzed using flow cytometry-based hematology (Bayer, Advia 120). Generation of an Ago2 antibody A synthetic peptide encompassing the first 25 amino acids of mouse Ago2 was coupled to KLH and was used as an immunogen in rabbits. Crude serum was obtained after the first boost and affinity-purified. This serum was then used in a 1:1000 dilution for Western blot analysis. Cell extract preparation and immunodetection of Ago2 Cells were lysed in 150 mM NaCl, 20 mM Tris (pH 7.5), 1 mM EDTA, 1% Triton X-100, and Complete protease inhibitors (Roche); after 10-min centrifugation at 13,000g, the supernatant was collected and used as extract for immunoblotting, using standard protocols. Retroviral transduction of Ago2−/− cells The coding sequences of Ago2 and Ago2D669A were inserted into the HpaI site of MigR retroviral vector, and recombinant retroviruses were produced and used to infect Ago2−/− bone marrow or fibroblasts as described (Pear et al. 1998). Reconstitution of lethally irradiated mice was performed as above. Derivation and manipulation of mouse embryonic fibroblast (MEF) cell lines Two Ago2fl/fl MEF cell lines (MEF lines 4 and 9) were derived from E12.5 embryos, transformed with SV40 large T-antigen-expressing retrovirus, and propagated under standard culture conditions. To generate Ago2−/− MEFs, both Ago2fl/fl MEF clones were infected with Cre-expressing adenovirus (AdenoCre; Vector Biolabs). For the miRNA-guided cleavage assay, the same assay as described in Pillai et al. (2005) was employed. MiRNA expression analysis Total RNA was isolated using Trizol (Invitrogen) according to the manufacturer’s instructions. MiRNA array profiling was performed as described (Miska et al. 2004). For clustering, only miRNAs with expression levels at least five times above background were selected. Expression data were log-transformed, gene-centered (mean), and normalized, and hierarchical clustering was performed using a correlation matrix and centroid linkage using the Cluster 3.0 algorithm. qRT–PCR expression analysis of miRNAs was performed using mirVana qRT–PCR miRNA detection kit (Ambion) and Roche LightCycler 480. Northern blotting of miRNAs was performed as described (Lau et al. 2001). Acknowledgments We thank M. Fabry, B. Coller, A. Shet, T. Hoffmann, M. Weiss, W. Pear, O. Shestova, R. Yi, and M. Busslinger for their helpful expertise, advice, and discussions. We thank K. Saigo for the Ago2 cDNA. We acknowledge S. Buonomo for advice in generating Ago2 antiserum. D.O’C. acknowledges the support of the Irvington Institute for Immunological Research and was their National Genetics Foundation Fellow. A.T. was supported by the Irene Diamond Foundation. Footnotes Supplemental material is available at http://www.genesdev.org. Article published online ahead of print. Article and publication date are online at http://www.genesdev.org/cgi/doi/10.1101/gad.1565607 References
|
PubMed related articles
Your browsing activity is empty. Activity recording is turned off. |
|||||||||||||
Cell. 2001 Jul 13; 106(1):23-34.
[Cell. 2001]Science. 2001 Aug 3; 293(5531):834-8.
[Science. 2001]Genes Dev. 2001 Oct 15; 15(20):2654-9.
[Genes Dev. 2001]Science. 2001 Sep 21; 293(5538):2269-71.
[Science. 2001]Nature. 2003 Nov 27; 426(6965):465-9.
[Nature. 2003]Science. 2004 Jan 2; 303(5654):83-6.
[Science. 2004]J Exp Med. 2005 May 2; 201(9):1367-73.
[J Exp Med. 2005]Cell. 2005 Dec 2; 123(5):819-31.
[Cell. 2005]J Exp Med. 2005 Jul 18; 202(2):261-9.
[J Exp Med. 2005]Science. 2004 Sep 3; 305(5689):1437-41.
[Science. 2004]Nature. 2005 Aug 4; 436(7051):740-4.
[Nature. 2005]Cell. 2005 Nov 18; 123(4):631-40.
[Cell. 2005]EMBO Rep. 2005 Oct; 6(10):961-7.
[EMBO Rep. 2005]Genes Dev. 2005 Dec 15; 19(24):2979-90.
[Genes Dev. 2005]Curr Biol. 2005 Dec 6; 15(23):2149-55.
[Curr Biol. 2005]Nat Genet. 2006 Mar; 38(3):356-62.
[Nat Genet. 2006]Genes Dev. 2005 Dec 15; 19(24):2979-90.
[Genes Dev. 2005]Nature. 2005 Aug 4; 436(7051):740-4.
[Nature. 2005]Cell. 2005 Nov 18; 123(4):631-40.
[Cell. 2005]EMBO Rep. 2005 Oct; 6(10):961-7.
[EMBO Rep. 2005]Cell. 2006 Nov 17; 127(4):747-57.
[Cell. 2006]Cell. 1999 Feb 5; 96(3):307-10.
[Cell. 1999]Genesis. 2000 Nov-Dec; 28(3-4):106-10.
[Genesis. 2000]Science. 1995 Sep 8; 269(5229):1427-9.
[Science. 1995]Blood. 2001 Dec 1; 98(12):3261-73.
[Blood. 2001]Nature. 2002 Apr 25; 416(6883):860-5.
[Nature. 2002]Blood. 1998 Nov 15; 92(10):3780-92.
[Blood. 1998]Science. 2005 Sep 2; 309(5740):1573-6.
[Science. 2005]Genome Biol. 2004; 5(9):R68.
[Genome Biol. 2004]Science. 2001 Oct 26; 294(5543):858-62.
[Science. 2001]